DK200500030U3 - Transdermalt plaster til indgivelse af fentanyl - Google Patents

Transdermalt plaster til indgivelse af fentanyl Download PDF

Info

Publication number
DK200500030U3
DK200500030U3 DK200500030U DKBA200500030U DK200500030U3 DK 200500030 U3 DK200500030 U3 DK 200500030U3 DK 200500030 U DK200500030 U DK 200500030U DK BA200500030 U DKBA200500030 U DK BA200500030U DK 200500030 U3 DK200500030 U3 DK 200500030U3
Authority
DK
Denmark
Prior art keywords
fentanyl
patch according
reservoir
patch
phase
Prior art date
Application number
DK200500030U
Other languages
English (en)
Inventor
Robert M Gale
Osdol William W Van
Shaoling Li
Stepic Jane
Venkatraman S Subramanian
Original Assignee
Alza Corp A Corp Of The State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23058257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200500030(U3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp A Corp Of The State filed Critical Alza Corp A Corp Of The State
Publication of DK200500030U1 publication Critical patent/DK200500030U1/da
Publication of DK200500030U3 publication Critical patent/DK200500030U3/da
Application granted granted Critical
Publication of DK200500030Y4 publication Critical patent/DK200500030Y4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Description

DK 2005 00030 W
Krav 1. Anlæg til kontinuerlig hydrolyse af en reaktionsblanding af et proteinholdigt animalsk eller vegetabilsk råmateriale, fortrinsvis et råmateriale i form af bieller affaldsprodukter fra oparbejdning af levnedsmidler, til mindst en flydende fase (13) og mindst en fast fase (12) hvor anlægget omfatter en klargøringssektion (1), en dermed forbundet hydrolysesektion (4), en med hydrolysesektionen (4) forbundet inaktiveringssektion (7) og en med inaktiveringssektionen (7) forbundet slut-bearbejdningssektion (17), hvor hydrolysesektionen (4) er af den type, der omfatter mindst én i hovedsagen rørformet hydrolysereaktor (6) med en første fremføringssnegl (20) til at drive en reaktionsblanding af enzym og råmateriale gennem den mindst ene rørformede hydrolysereaktor (6) og videre over i inaktiveringssektionen (7), der har mindst én med hydrolysesektionen (4) forbundet inaktiveringsreaktor (8) med en indløbsende (9) og en modsat denne lokaliseret udløbsende (10), kendetegnet ved, - at den mindst ene inaktiveringsreaktor (8) udløbsende (10) har mindst et udtag (14) til den faste fase (12) og mindst et i afstand fra udtaget (14) til den faste fase (12) lokaliseret udtag (16) til den flydende fase (13), at inaktiveringsreaktoren (8) har en anden fremføringssnegl (24) til at forskyde indholdet i inaktiveringsreaktoren (8) frem mod udtaget (16), - at inaktiveringsreaktoren (8) har en ved sin bund arrangeret tredje fremføringssnegl (25) til at forskyde sedimenteret fast stof frem og ud gennem udtaget (14) for den faste fase (12), og at der ved udtaget (16) til den flydende fase (13) er arrangeret midler (15) til at blande en vandig fase med en fedtfase.
5 2 5 2 3 10 4 15 20 5 25 6 30 7 35 8
DK 2005 00030 W
Anlæg ifølge krav 1, kendetegnet ved, at mindst én af fremføringssneglene (20,24,25) er af den type, der er indrettet til at rotere med uret i et fastlagt første tidsrum, og mod uret i fastlagt andet efterfølgende tidsrum.
Anlæg ifølge ethvert af kravene 1 eller 2, kendetegnet ved, at mindst én af fremføringssneglene (20,24,25) er udformet med skovle eller plader (22) i et område ved periferien på fremføringssneglens (20,24,25) vindinger (21) .
Anlæg ifølge ethvert af kravene 1, 2 eller 3, kendetegnet ved, at udtagene (16) til den flydende fase (13) omfatter et fedtudtag til en fedtfraktion og mindst et proteinudtag, til en vandig fraktion, der indeholder bestanddele valgt fra gruppen af vandopløselige aminosyrer, peptider og/eller proteiner, vanduopløselige eller tungtopløselige aminosyrer, peptider og/eller protein, eller blandinger af disse bestanddele.
Anlæg ifølge ethvert af kravene 1-4, kendetegnet ved, at den vandige fase omfatter opløste og uopløste bestanddele af proteinoprindelse.
Anlæg ifølge krav 5, kendetegnet ved, at midlerne til at blande den vandige fase med fedtfasen er en blandepropel (15 ) eller en cirkulationspumpe.
Anlæg ifølge krav 6, kendetegnet ved, at vandopløselige og vanduopløselige bestanddele af proteinoprindelse og fedtfraktionen skilles fra hinanden i en kontinuerligt virkende dekanter eller trikanter.
Fremgangsmåde til kontinuerligt at hydrolysere en reaktionsblanding af et proteinholdigt animalsk eller
DK 2005 00030 W
vegetabilsk råmateriale til en flydende fase (13) og en fast fase (12) i et anlæg ifølge krav 1 - 7, omfattende trinnene at neddele råmaterialet, at blande råmaterialet med enzym, enzymatisk at hydrolysere råmaterialet i et fastlagt tidsrum, at inaktivere enzymer, der er tilstede i reaktionsblandingen, i en inaktiveringsreaktor (8), kontinuerligt at udtage den faste fase (12) og den flydende fase (13) fra reaktionsblandingen i inaktiveringsreaktoren (8), kendetegnet ved, at den flydende fase (13) omfatter en fedtfraktion og en vandig fraktion med et indhold af opløste og uopløste bestanddele af proteinoprindelse, at fedtfraktionen og vandfraktionen udtages fra inaktiveringsreaktoren (8) kontinuerligt enten hver for sig med ens eller forskellig hastighed eller som en samlet homogeniseret suspension.
9. Fremgangsmåde ifølge krav 8, kendetegnet ved, at de opløste og uopløste bestanddele af proteinoprindelse og fedtfasen efterfølgende separeres i en trikanter eller dekanter.
10. Fremgangsmåde ifølge krav 8 eller 9, kendetegnet ved, at fremgangmåden omfatter et indledende trin hvor metaldele udskilles fra råmaterialet.
DK 2005 00030 W
KRAV
1. Et transdermalt plaster til indgivelse af fentanyl eller en analog deraf gennem huden omfattende (a) et bagsidelag; (b) et reservoir fordelt på bagsidelaget, idet i det mindste den hudkontaktende overflade af reservoiret er selvklæbende; hvori reservoiret omfatter en enkeltfase polymersammensætning fri for uopløste bestanddele indeholdende en tilstrækkelig mængde fentanyl eller en analog deraf til at inducere og vedligeholde smertelindring hos et menneske i mindst tre dage.
2. Et plaster ifølge krav 1, som indeholder fentanyl.
3. Et plaster ifølge krav 1, som indeholder alfentanil, lofentanil, remifentanil eller sufentanil som fentanylanalog.
4. Et plaster ifølge krav 3, hvori fentanylanalogen er sufentanil.
5. Et plaster ifølge et hvilket som helst af krav 1 til 4, som er bioækvivalent til det transdermale DURAGESIC® fentanylsystem.
6. Et plaster ifølge et hvilket som helst af krav 1 til 5, hvori reservoiret er dannet af et klæbestof.
7. Et plaster ifølge krav 6, hvori reservoiret er dannet på grundlag af en klæbende polymer.
8. Et plaster ifølge krav 7, hvori den klæbende polymer er et polyacrylatklæbestof.
9. Et plaster ifølge krav 8, hvori polyacrylatklæbestoffet har et Tg mindre end -10eC.
10. Et plaster ifølge et hvilket som helst af krav 1 til 9, hvori plasteret udviser et normaliseret Cmax på 3,3 til 82,5 ng/ml-(mg/time).
11. Et plaster ifølge krav 10, hvori plasteret udviser et steady-state lægemiddelflux på 0,1 til 20 pg/cm2/time, fortrinsvis 1 til 10 pg/cm2/time.
DK 2005 00030 W
12. Et plaster ifølge et hvilket som helst af krav 1 til 11, hvori plasteret udviser et standardiseret Cmax på 0,001 til 0,2 ng/ml-cm.
13. Et plaster ifølge et hvilket som helst af krav 1 til 12, hvori reservoiret omfatter en tilstrækkelig mængde opløst fentanyl eller analog deraf til at inducere og vedligeholde smertelindring i 3-7 dage.
14. Et plaster ifølge krav 13, hvori reservoiret omfatter en polymer med en solubilitet for fentanyl eller en analog deraf på 1 vægt-% til 25 vægt-%, fortrinsvis 7 vægt-% til 12 vægt-%.
15. Et plaster ifølge krav 13 eller 14, hvori reservoiret omfatter 0,05 til 1,75 mg/cm2, fortrinsvis 0,08 til 1,25 mg/cm2, mere foretrukket 0,1 til 0,75 mg/cm2, mest foretrukket 0,12 til 0,5 mg/cm2 fentanyl eller en analog deraf.
16. Et plaster ifølge et hvilket som helst af krav 13 til 15, hvori reservoiret har en tykkelse på 0,0125 mm (0,5 mil) til 0,1 mm (4 mil).
17. Et plaster ifølge et hvilket som helst af krav 1 til 16, hvori reservoiret yderligere omfatter et permeationsforøgende middel.
18. Et plaster ifølge et hvilket som helst af krav 1 til 17, hvori bagsidelaget omfatter et polyurethan, polyvinylacetat, polyvinylidenchlorid, polyethylen, polyethylenterephthalat (PET), PET-polyolefinlaminat eller en polybutylenterephthalatpolymer.
19. Et plaster ifølge krav 18, hvori bagsidelaget omfatter et lav densitet polyethylen (LDPE) materiale, et middel densitet polyethylen (MDPE) materiale elleret høj densitet polyethylen (HDPE) materiale.
20. Et plaster ifølge krav 19, hvori bagsidelaget omfatter et lav densitet polyethylen (LDPE) materiale.
21. Et plaster ifølge et hvilket som helst af krav 18 til 20, hvori bagsidelaget har en tykkelse på 0,012 mm (0,5 mil) til 0,125 mm (5 mil).
22. Et transdermalt plaster ifølge et hvilket som helst af krav 1 til 21 til indgivelse af fentanyl omfattende et selvklæbende fentanylreservoir på et bagsidelag; idet reservoiret omfatter en enkeltfase polymersammensætning fri for uopløste bestanddele indeholdende et polyacrylatklæbestof med tilstrækkelig solubilitet for fentanyl til at indeholde opløst fentanyl i en tilstrækkelig mængde til at inducere og vedligeholde smer-
DK 2005 00030 W
telindring hos et menneske i mindst tre dage, idet plasteret udviser et normaliseret
Cmax på 3,3 til 82,5 ng/ml-{mg/time).
23. Et transdermalt plaster ifølge et hvilket som helst af krav 1 til 22 til indgivelse af fentanyl omfattende et selvklæbende fentanylreservoir på et bagsidelag; idet reservoiret omfatter en enkeltfase polymersammensætning fri for uopløste bestanddele indeholdende et polyacrylatklæbestof med tilstrækkelig solubilitet for fentanyl til at indeholde opløst fentanyl i en tilstrækkelig mængde til at inducere og vedligeholde smertelindring hos et menneske i mindst tre dage, idet plasteret udviser et standardiseret Cma)( på 0,01 til 0,2 ng/ml-cm2.
24. Et transdermalt plaster ifølge et hvilket som helst af krav 1 til 22 til indgivelse af sufentanil omfattende et selvklæbende fentanylreservoir på et bagsidelag; idet reservoiret omfatter en enkeltfase polymersammensætning fri for uopløste bestanddele indeholdende et polyacrylatklæbestof med tilstrækkelig solubilitet for sufentanil til at indeholde opløst sufentanil i en tilstrækkelig mængde til at inducere og vedligeholde smertelindring hos et menneske i mindst tre dage, idet plasteret udviser et normaliseret Cmax på fra 0,04 til 10 ng/ml-(mg/time).
25. Et transdermalt plaster ifølge et hvilket som helst af krav 1 til 22 til indgivelse af sufentanil omfattende et selvklæbende fentanylreservoir på et bagsidelag; idet reservoiret omfatter en enkeltfase polymersammensætning fri for uopløste bestanddele indeholdende et polyacrylatklæbestof med tilstrækkelig solubilitet for sufentanil til at indeholde opløst sufentanil i en tilstrækkelig mængde til at inducere og vedligeholde smertelindring hos et menneske i mindst tre dage, idet plasteret udviser et standardiseret Cmax på fra 0,001 til 0,05 ng/ml-cm2.
26. Et plaster ifølge et hvilket som helst af krav 1 til 25, som er fuldstændig fri for en hastighedsregulerende membran.
DK 2005 00030 W
FIG. 2
DK 2005 00030 W
O N. II 2: <N Φ ' 11 "ΪΧ io. to^ s: ..α to co CL- i LU11 £qφ Φ o c; C S, ctj ctf ra C C g^ Æ § =3 =3 uz co co _p -^P v^p θ'- θ'- o'' CO O) Co '5 '5 ’£ S -G -S c: c; c: •s ^ « co co co v^p o * θ'- o'- CO 'sr 03 Φ φ <jl· φ Φ Φ
co
(QLUjj/zUJQ/Bri) xny . 24_.:_ J6_______48_ Middel-Tider (Timer) FIG. 4 " (euji)/zLUD/6rl) xny
DK 2005 00030 W
C3 lC (dLU!i/zUJD/6r1) xny
Vægt % Lægemiddel φω!ΐ/ζωο/6ί1) xn/j>
DK 2005 00030 W
DURAGESIC® Plaster (100 '/tlme)^40.cm Fentanyl Plaster 20 cm2 Fentanyl Plaster 40 cm2
/uj/I5u uoi)ej)udouo}i turnes
DK 2005 00030 W
DURAGESIC® 100 pg/time Fentanyl Plaster 100 pg/time (n=31) -
Tid (Timer)
DK200500030U 2001-03-16 2005-01-25 Transdermalt plaster til indgivelse af fentanyl DK200500030Y4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27683701P 2001-03-16 2001-03-16

Publications (3)

Publication Number Publication Date
DK200500030U1 DK200500030U1 (da) 2005-05-13
DK200500030U3 true DK200500030U3 (da) 2005-07-22
DK200500030Y4 DK200500030Y4 (da) 2006-07-28

Family

ID=23058257

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02715112T DK1381352T3 (da) 2001-03-16 2002-03-15 Plaster til transdermal indgivelse af fentanyl
DK200500030U DK200500030Y4 (da) 2001-03-16 2005-01-25 Transdermalt plaster til indgivelse af fentanyl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02715112T DK1381352T3 (da) 2001-03-16 2002-03-15 Plaster til transdermal indgivelse af fentanyl

Country Status (22)

Country Link
US (11) US20030026829A1 (da)
EP (1) EP1381352B1 (da)
JP (7) JP5354763B2 (da)
KR (1) KR100904158B1 (da)
CN (2) CN101524339A (da)
AT (4) ATE364380T1 (da)
CA (1) CA2440884C (da)
CY (1) CY1106834T1 (da)
CZ (1) CZ307857B6 (da)
DE (3) DE02715112T1 (da)
DK (2) DK1381352T3 (da)
ES (1) ES2270746T3 (da)
FI (2) FI6962U1 (da)
HK (1) HK1068545A1 (da)
IL (3) IL157822A0 (da)
MX (1) MXPA03008349A (da)
NZ (1) NZ528148A (da)
PL (1) PL363079A1 (da)
PT (1) PT1381352E (da)
RU (2) RU2708563C2 (da)
WO (1) WO2002074286A1 (da)
ZA (1) ZA200308026B (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
CA2440884C (en) * 2001-03-16 2012-05-22 Alza Corporation Transdermal patch for administering fentanyl
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AR039336A1 (es) * 2002-04-23 2005-02-16 Alza Corp Sistemas analgesicos transdermicos con potencial de abuso reducido
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2003101433A1 (de) * 2002-05-28 2003-12-11 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend fentanylum
DE10223835A1 (de) * 2002-05-28 2003-12-11 Labtec Gmbh Pflaster, enthaltend Fentanylum
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
TWI296531B (en) 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
US20040086551A1 (en) 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
MXPA05008366A (es) * 2003-02-07 2005-11-04 Lohmann Therapie Syst Lts Sistema terapeutico transdermico adecuado para la aplicacion de calor para promover la penetracion de sustancias activas y el uso del mismo.
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
KR20060120678A (ko) 2003-10-30 2006-11-27 알자 코포레이션 남용될 가능성이 감소된 경피용 진통제 시스템
PT1530967E (pt) 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
US20070269522A1 (en) * 2004-08-20 2007-11-22 Wold Chad R Transdermal Drug Delivery Device with Translucent Protective Film
WO2006029192A1 (en) * 2004-09-08 2006-03-16 Dermatrends, Inc. Transdermal delivery of hydrophobic bioactive agents
US8252320B2 (en) * 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
AU2012201164B2 (en) * 2004-10-21 2014-07-24 Durect Corporation Transdermal delivery systems
EP2216018B1 (en) * 2004-10-21 2012-04-04 Durect Corporation Transdermal delivery systems
GB0509276D0 (en) * 2005-05-06 2005-06-15 Univ Cranfield Synthetic receptor
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
TWI419717B (zh) * 2005-06-17 2013-12-21 Altea Therapeutics Corp 滲透傳送系統及其使用方法
WO2007011987A2 (en) * 2005-07-18 2007-01-25 Alza Corporation Device and method for increasing the throughput of irritation testing of transdermal formulations
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
WO2007035942A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal risperidone delivery system
EP2308480B1 (en) * 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
WO2007095147A2 (en) * 2006-02-13 2007-08-23 Aveva Drug Delivery Systems Adhesive preparation comprising sufentanil and methods of using the same
WO2007121949A1 (en) * 2006-04-21 2007-11-01 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Transdermal delivery system comprising sufentanil and its analogues
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
US20080004671A1 (en) * 2006-06-28 2008-01-03 Alza Corporation Vagus nerve stimulation via orally delivered apparatus
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
FR2912643B1 (fr) * 2007-02-15 2009-04-17 Dbv Technologies Sa Patch pour application cutanee
JP5192722B2 (ja) * 2007-04-27 2013-05-08 祐徳薬品工業株式会社 外用貼付剤
WO2009005814A2 (en) * 2007-07-03 2009-01-08 Marchitto Kevin S Drug-delivery patch comprising a dissolvable layer and uses thereof
JP5451613B2 (ja) 2007-08-06 2014-03-26 アラーガン、インコーポレイテッド デスモプレシン薬物送達のための方法及びデバイス
KR101583680B1 (ko) * 2007-10-15 2016-01-08 알자 코퍼레이션 펜타닐의 1일-1회 교체 경피 투여
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
EP2246054B1 (en) 2008-01-28 2018-06-13 Teikoku Seiyaku Co., Ltd. Fentanyl-containing patch for external use
EP2111857A1 (de) 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
ES2710454T3 (es) 2008-05-21 2019-04-25 Ferring Bv Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia
CN101780057B (zh) * 2009-01-21 2012-09-05 考司美德制药株式会社 经皮吸收贴剂
SG176133A1 (en) 2009-07-24 2011-12-29 Teikoku Seiyaku Kk Fentanyl-containing adhesive preparation for external use
EP2295046B1 (de) 2009-09-14 2012-12-19 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
JP5927506B2 (ja) 2010-04-13 2016-06-01 レルマダ セラピューティクス、インク． １−メチル−２’，６’−ピペコロキシリダイドの皮膚医薬組成物および使用方法
EP2462927A1 (en) 2010-12-03 2012-06-13 Hexal AG Transdermal therapeutic system comprising fentanyl
KR20120107153A (ko) 2011-03-15 2012-10-02 아이큐어 주식회사 펜타닐 경피 패치제
WO2013042989A1 (ko) 2011-09-22 2013-03-28 주식회사 트랜스덤 펜타닐 및 이의 동족체를 함유하는 경피 흡수성 제제
EP2599478A1 (de) * 2011-11-30 2013-06-05 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
ES2784756T3 (es) 2014-07-18 2020-09-30 Buzzz Pharmaceuticals Ltd Parche transdérmico opioide/antagonista de opioides disuasivo del abuso
BR112017003248B1 (pt) * 2014-08-25 2022-10-11 Henkel IP & Holding GmbH Composição compreendendo copolímero acrílico
JP6940407B2 (ja) 2014-12-19 2021-09-29 キンデーバ ドラッグ デリバリー リミティド パートナーシップ フェンタニルを含む経皮薬物送達デバイス
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
EP3067050A1 (en) 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
EP3556359A4 (en) 2016-12-19 2020-08-05 Nutritape, S.L. ENERGIZING PLASTER FOR SPORTS
CN110536861B (zh) 2017-04-18 2023-07-04 突破技术有限责任公司 硫的生产
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020008370A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
RU2712918C1 (ru) * 2019-08-01 2020-02-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ предотвращения острой боли при выполнении химического плевродеза после радикальных торакопластических операций онкологического характера
CN110693857B (zh) * 2019-10-17 2023-08-11 宜昌人福药业有限责任公司 一种舒芬太尼透皮贴剂及其制备方法
US11229611B2 (en) 2020-04-30 2022-01-25 Taho Pharmaceuticals Ltd. Clobazam transdermal delivery system and uses thereof
RU204475U1 (ru) * 2020-09-24 2021-05-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт медицины труда имени академика Н.Ф. Измерова" (ФГБНУ "НИИ МТ") Медицинский аппликатор для местного лечения кожных заболеваний
US11369789B2 (en) 2021-04-05 2022-06-28 Ishaan Jain Transdermal drug delivery system

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352708A (en) * 1964-03-02 1967-11-14 Ball Brothers Co Inc Glass having dual protective coatings thereon and method for forming such coatings
US3886126A (en) * 1973-04-09 1975-05-27 Monsanto Co Solutions of pressure-sensitive resin solutions with improved viscosity and flow
US3900610A (en) * 1973-04-09 1975-08-19 Monsanto Co Process of making a pressure sensitive adhesive article
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS57142258A (en) * 1981-02-27 1982-09-02 Nitto Electric Ind Co Drug containing tape preparation
US5310559A (en) * 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4954343A (en) * 1986-03-29 1990-09-04 Nitto Electric Industrial Co., Ltd. Dermal pharmaceutical preparations
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4822802A (en) * 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US5186939A (en) * 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
JPH0818975B2 (ja) * 1987-06-08 1996-02-28 日東電工株式会社 疾患治療用貼付剤
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5364630A (en) * 1988-06-14 1994-11-15 Alza Corporation Subsaturated nicotine transdermal therapeutic system
CA2065311C (en) * 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
JP3046346B2 (ja) * 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
RU2056865C1 (ru) * 1992-02-25 1996-03-27 Новокузнецкий филиал Института общей реаниматологии РАМН Способ лечения печеночной недостаточности у больных с эндо- и экзогенными токсикозами
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
WO1995009006A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer
DK0781122T3 (da) 1994-09-14 2000-10-30 Minnesota Mining & Mfg Matrix til transdermal lægmiddelafgivelse
US5714162A (en) * 1994-09-16 1998-02-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Scopolamine patch
KR100188180B1 (ko) * 1994-12-24 1999-06-01 서경배 경피투여용 패취제제
US6154190A (en) * 1995-02-17 2000-11-28 Kent State University Dynamic drive methods and apparatus for a bistable liquid crystal display
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US6093419A (en) * 1995-06-07 2000-07-25 Lectec Corporation Compliance verification method and device in compulsory drug administration
US5693335A (en) * 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
DE19527925C2 (de) * 1995-07-29 1997-07-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer trennmittelbeschichteten Schutzschicht
US5900198A (en) * 1996-01-31 1999-05-04 Hori; Yasunori Method of producing molded resin product
TW411277B (en) * 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
JP3836566B2 (ja) * 1996-05-13 2006-10-25 久光製薬株式会社 フェンタニル含有経皮投与テープ製剤
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
AU4990797A (en) * 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DE19653606A1 (de) * 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6267984B1 (en) * 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
KR19980025307A (ko) * 1998-04-11 1998-07-06 조태임 진통효과를 갖는 약물의 경피흡수제제
PT1061900E (pt) * 1999-01-14 2005-04-29 Noven Pharma Composicoes e metodos para libertacao de uma droga
DE60045153D1 (de) * 1999-04-13 2010-12-09 Hisamitsu Pharmaceutical Co Zubereitungen zur perkutanen absorption
IT1312198B1 (it) * 1999-04-21 2002-04-09 De Nora Spa Cella a combustibile raffreddata mediante iniezione diretta di acqualiquida
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
KR20010036685A (ko) * 1999-10-11 2001-05-07 김윤 펜타닐을 함유하는 매트릭스형 경피투여제
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6455066B1 (en) * 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
CA2440884C (en) * 2001-03-16 2012-05-22 Alza Corporation Transdermal patch for administering fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
ATE403420T1 (de) * 2002-03-06 2008-08-15 Hexal Ag Transdermalsystem mit fentanyl
AR039336A1 (es) * 2002-04-23 2005-02-16 Alza Corp Sistemas analgesicos transdermicos con potencial de abuso reducido
TWI296531B (en) * 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
DE10252725A1 (de) * 2002-11-13 2004-06-03 Lts Lohmann Therapie-Systeme Ag Feuchtigkeitsaktivierbare Klebstoffe für medizinische Anwendungszwecke
KR20060120678A (ko) * 2003-10-30 2006-11-27 알자 코포레이션 남용될 가능성이 감소된 경피용 진통제 시스템
JP4745747B2 (ja) * 2004-08-12 2011-08-10 日東電工株式会社 フェンタニル含有貼付製剤
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery

Also Published As

Publication number Publication date
JP6437971B2 (ja) 2018-12-12
ES2270746T3 (es) 2007-12-01
ATE364380T1 (de) 2007-07-15
US20030026829A1 (en) 2003-02-06
US20040213832A1 (en) 2004-10-28
JP2012197302A (ja) 2012-10-18
US20140030316A1 (en) 2014-01-30
IL243302A0 (en) 2016-02-29
FI7341U1 (fi) 2006-12-27
JP2014224145A (ja) 2014-12-04
AT9258U3 (de) 2008-05-15
HK1068545A1 (en) 2005-04-29
DK200500030U1 (da) 2005-05-13
US20180098979A1 (en) 2018-04-12
CZ307857B6 (cs) 2019-07-03
JP5950704B2 (ja) 2016-07-13
DE60220661D1 (de) 2007-07-26
US20140271799A1 (en) 2014-09-18
EP1381352A1 (en) 2004-01-21
JP2018109021A (ja) 2018-07-12
CN100508974C (zh) 2009-07-08
DK1381352T3 (da) 2007-07-09
AT9258U2 (de) 2007-07-15
NZ528148A (en) 2006-02-24
EP1381352B1 (en) 2007-06-13
JP5354763B2 (ja) 2013-11-27
RU2351318C2 (ru) 2009-04-10
RU2003127841A (ru) 2005-03-27
WO2002074286A1 (en) 2002-09-26
CN101524339A (zh) 2009-09-09
JP2017014268A (ja) 2017-01-19
DE02715112T1 (de) 2007-04-19
DE20221841U1 (de) 2008-05-21
JP2011037884A (ja) 2011-02-24
US20190167655A1 (en) 2019-06-06
IL157822A0 (en) 2004-03-28
AU2002247331C1 (en) 2002-10-03
US20200054619A1 (en) 2020-02-20
CN1535142A (zh) 2004-10-06
US20210113541A1 (en) 2021-04-22
RU2708563C2 (ru) 2019-12-10
CY1106834T1 (el) 2012-05-23
US20090004257A1 (en) 2009-01-01
AT8273U1 (de) 2006-05-15
FIU20050202U0 (fi) 2005-06-02
DK200500030Y4 (da) 2006-07-28
ZA200308026B (en) 2004-10-15
CZ20032813A3 (cs) 2004-08-18
IL157822A (en) 2016-05-31
FI6962U1 (fi) 2006-02-13
FIU20060295U0 (fi) 2006-07-11
JP2004524336A (ja) 2004-08-12
KR20030082995A (ko) 2003-10-23
JP2020023541A (ja) 2020-02-13
AT8585U2 (de) 2006-10-15
DE60220661T2 (de) 2008-02-14
PL363079A1 (en) 2004-11-15
PT1381352E (pt) 2007-07-27
CA2440884C (en) 2012-05-22
US20200289488A1 (en) 2020-09-17
AT8585U3 (de) 2007-02-15
RU2007113373A (ru) 2008-10-27
ES2270746T1 (es) 2007-04-16
CA2440884A1 (en) 2002-09-26
KR100904158B1 (ko) 2009-06-23
US20160331740A1 (en) 2016-11-17
MXPA03008349A (es) 2004-10-15

Similar Documents

Publication Publication Date Title
DK200500030U3 (da) Transdermalt plaster til indgivelse af fentanyl
JP5882970B2 (ja) 活性物質ブプレノルフィンを投与するための経皮治療システム
US6417227B1 (en) Methods of delivery of cetyl myristoleate
RU2445959C2 (ru) Новый лейкопластырный препарат
CZ287373B6 (en) Transdermal therapeutic system
AU2006343077A1 (en) Tansdermally absorbable preparation comprising anti-dementia agent
CZ262096A3 (en) Hydrophilic adhesive
US20080254073A1 (en) Transdermal Patch Comprising Paroxetine
US5989585A (en) Transdermal therapeutic system (TTS) containing vitamin E for the treatment of drug dependency
WO2007009320A1 (fr) Préparation de statines pour libération prolongée
JP2024091648A (ja) 新規な経口組成物
US20210113486A1 (en) Multi-segmented transdermal dosing unit and methods of use
WO2003047494A3 (en) Reverse micelle compositions and uses thereof
CZ296693B6 (cs) Transmukozální preparáty s levosimendanem
US20070065496A1 (en) Dermal therapeutic system comprising 2-(3-benzophenyl)propionic acid
JP2000204099A (ja) ペプチド含有液の精製方法
NO178784B (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system med norpseudoefedrin som virkestoff
AU4035499A (en) Laminate for application onto an acceptor
CN110464713B (zh) 奇壬醇抗风湿关节炎的透皮贴剂制备方法
KR100245773B1 (ko) 알긴산을 이용한 서방성 의약 전달 시스템용 알긴산 비드(bead) 및 그 제조방법
RU2122418C1 (ru) Средство для лечения хронического гепатита неинфекционной этиологии
CA3069044A1 (en) Transdermal therapeutic system with low total fampridine content
Nishimoto et al. RETRACTED: DL–/PO–phosphatidylcholine serves as a memory enhancer for normal healthy subjects
KR20040018672A (ko) 에스(+)-이부프로펜을 함유하는 경피투여용 조성물 및이를 함유하는 경피투여용 패취제
WO2008136699A1 (fr) Patch transdermique à microcapsules et procédé de fabrication correspondant

Legal Events

Date Code Title Description
URA Request for termination filed (utility model)
UDM Result of invalidation request: utility model maintained in full
UUP Utility model expired